Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Find out how a multidisciplinary team of scientists came to create England's new way to identify how to fight and track TB outbreaks using DNA analysis.

Interviewees in order of appearance:

  • Dr Nicola Fawcett: Clinical Research Fellow and a Doctor in Acute and General Medicine; Nicola studies antibiotic prescribing and the effects on antimicrobial resistance in the gut bacteria.
  • Dr Jessica Hedge: Population Geneticist; Jessica studies how DNA analysis can be used to understand how bacteria evolve and develop drug resistance.
  • Dr Timothy Walker: Academic Clinical Lecturer and Doctor in Microbiology/Infectious Diseases; Timothy studies how DNA analysis can be used to predict drug resistance, understand transmission of infections, and inform patient care.
  • Professor Derrick Crook: Research Group Lead and Direct of the National Infection Service at Public Health England; Derrick has led the group in pioneering the use of DNA analysis from laboratory to patient care.
  • Dr Dilrini de Silva: Bioinformatician; Dilrini designs and performs complex, large scale computational analyses of bacterial DNA to provide information on drug resistance and transmission of infections.

Interview Transcript

Dr Nicola Fawcett: So let's say the patient comes in with pneumonia, obviously we'll hear the patient's experience and see what's been going on, listen to their chest and do a chest X ray, and that will tell us that maybe there's a severe infection in the lungs, but it won't tell us what the cause of it is. So we'll know from previous experience that it's maybe one of a number of five or six suspects. And we'll treat the patient with antibiotics that would cover most of those suspects. But what we'll also do is do a blood test and we'll have the bacteria in the blood tests we can grow in a lab, and that will tell us which antibiotics are going to work. Now the research group uses an entirely new technique where they break open the bacteria and extract the DNA.

Dr Jessica Hedge: Tuberculosis in particular, is a slow growing bacterium. So it can take up to six weeks to grow each one individually to see whether it is resistant to any of those drugs and the benefit of performing whole genome sequencing is that you have your sequence very quickly within a matter of days and from that, you can work out which antibiotics it would be resistant to.

Dr Timothy Walker: So in the old world, you are doing a dozen different tests, each of which costs money. In the New World, you sequence the genome of the bacterium and from that, you derive all the information you need to answer all of the questions you want to ask. What species is it? Which other TB samples is it related to? Which drugs is it resistant to? And which will kill it? And it's just one test, and it costs about the same amount of money as one of the many other tests we currently use.

Prof Derrick Crook: It is extraordinary that this is immediately available, and even just 10 years ago, it might have taken me months, even years to get the complete picture.

Dr Dilrini De Silva: If we have DNA sequencing data available, once the sequencing run is done, we can process it through our bioinformatics workflows and be able to provide you all that information in a matter of hours.

Dr Jessica Hedge: In recent study, we achieved very high accuracy and also precision in predicting whether a particular TB sample is going to be resistant to a particular drug or not.

Prof Derrick Crook: Now we have past that comparative study, and we demonstrating the performance that we needed to have. Therefore, the decision was made to commit Public Health England to implementing it.

Dr Timothy Walker: Science is day after day of fairly menial grinding work, collecting data, cleaning it, making sense of it. Then every now and again, you get an extraordinary high when you look at the results and you see something new and you realise you're the first person in the world who's ever seen this.

Read more about the study (as well as the original paper) on the Modernising Medical Microbiology website.

Derrick Crook

Infectious Diseases & Microbiology

Professor Derrick Crook developed a research programme in translating whole genome sequencing of pathogens and linkage of patient data contained in hospital databases. By linking whole genomic typing of pathogens with this patient data, his research is leading to more rapid and effective diagnosis, management and tracking of common infections such as MRSA (methicillin-resistant Staphylococcus aureus), Clostridium difficile, Tuberculosis and Norovirus.

More podcasts related to Translational & Clinical

David Stuart: Structural biology and vaccines

The basis of an effective vaccine is that a pathogen is physically recognised by the immune system.

Kay Grunewald: Structural cell biology of virus infection

Understanding the entirety of a virus’ ‘life cycle’ requires an understanding of its transient structures at the molecular level. Using imaging techniques allows us to understand the communication between the virus and the components of the cell it is infecting, which can ultimately help to treat infectious diseases.

Jens Rittscher: Biological imaging

Video microscopy aims to improve target discovery and drug development and to do so generates large volumes of data. Fluorescence labelling helps make intrinsic cellular functions visible and computational tools then enable analysis of these data sets to improve our understanding of cellular functions.

Sebastian Nijman: Pharmacogenomics

In the context of cancer, genetic diversity means that we respond differently to various treatments. Pharmacogenomics sits at the intersection between genetics and drugs. Better understanding of the genetic landscape of cancer and the recent increase of targeted drugs allow us to better match patients with the best treatments, improving care.

Ian Pavord: Asthma

Ian Pavord's research in to airway inflammation has resulted in mepolizumab being identified as an effective inhibitor of eosinophilic inflammation and asthma attacks. Mepolizumab is currently in Phase III clinical trials and if found to be effective could be a promising treatment for certain asthma patients.

Trudie Lang: The Global Health Network

The Global Health Network is a successful and growing online science park comprised of varied research communities for different health research groups and cross-cutting health topics. It is built for the research and wider health community by researchers and public health practitioners themselves. It is a trusted source of quality information, education and research tools.

Najib Rahman: Respiratory Medicine

Respiratory medicine encompasses a large number of common diseases like pneumonia, asthma, emphysema and lung cancer. Outcomes are currently relatively poor and the area of research is underfunded. Recent progress have been made towards personalising treatment, and Dr Rahman's research aims at improving patient care.

Chris O’Callaghan: Atherosclerosis & immunity

Atherosclerosis is the most important cause of death worldwide. It is caused by the accumulation of both fatty material and immune cells. Over time, these set up an inflammatory reaction which causes a lot of damage to the blood vessel wall. Although we do have good therapies designed to lower the levels of fatty material, we haven’t any therapies specifically designed to target the effect of the immune system. Professor O'Callaghan's group is working towards developing such therapies.

Stefan Knapp: Development of chemical probes

While drugs were initially developped by testing natural products directly in humans, the current approach is to use chemical probes. These are small chemical coumpounds that inhibit selected targets, avoiding side effects. Professor Knapp produces structures of molecular targets and makes them widely available. This will allow a faster and more cost effective development of new drugs.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.